Aclaris Therapeutics (NASDAQ:ACRS) Issues Quarterly Earnings Results

Aclaris Therapeutics (NASDAQ:ACRS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04, FiscalAI reports. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The firm had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.27 million.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $3.90 on Friday. The business’s 50 day moving average price is $4.62 and its 200-day moving average price is $4.53. Aclaris Therapeutics has a 1 year low of $2.10 and a 1 year high of $6.60. The firm has a market capitalization of $545.30 million, a PE ratio of -6.72 and a beta of 0.96.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ACRS. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday, October 28th. Finally, Canaccord Genuity Group raised their target price on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has an average rating of “Buy” and a consensus target price of $11.33.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.